TEC
TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.
Overview
Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Oesophageal Squamous Cell Carcinoma. In OnCo, 2 product records name it (Ibrutinib and Acalabrutinib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.
- 1 · What it is
TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.
- 2 · What goes wrong in cancer
Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton.
- 3 · How drugs use it
No product in this corpus aims at TEC yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:11719 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42680 (protein name, function text, keywords and locations (REST API)); IntOGen TEC (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. Required for TCR-dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific substrate, and contributes to CD28-signalling. Mediates signals that negatively regulate IL2RA expression induced by TCR cross-linking. Location: Cytoplasm; Cell membrane; Cytoplasm, cytoskeleton (UniProt). Locus 4p12-p11 (HGNC).
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCC)
- Oesophageal squamous cell carcinoma: IntOGen driver in 1 cohort (ESCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: 2 OnCo product records name it; IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TEC" OR ABSTRACT:"TEC" OR TITLE:"tec protein tyrosine kinase" OR ABSTRACT:"tec protein tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Tec" OR ABSTRACT:"Tyrosine-protein kinase Tec" OR TITLE:"PSCTK4" OR ABSTRACT:"PSCTK4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TEC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCLIP1
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
- TargetRAP1GDS1
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
- TargetZBTB16
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
- TargetMSN
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Acalabrutinib, Ibrutinib.
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
- TrialSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.